TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15312013

Group type: EXPERIMENTAL
Intervention: Forced-air warmer (WarmTouch 5700)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Forced-air warmer (Bair Hugger 500)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiant heater (Aragona Thermal Ceilings CTC X)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiant heater (self assembled radiant heater of 4 Hydrosun 500 infrared lamps)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard hospital blanket)
Number of subjects: 50
Study: 11587671

Group type: EXPERIMENTAL
Intervention: Back school program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control session (3 months after back school program)
Number of subjects: 44
Study: 9869546

Group type: EXPERIMENTAL
Intervention: ABG monitor (SensiCath; Optical Sensors Inc.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard clinical laboratory analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABG monitor
Number of subjects: 30
Study: 7978435

Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine administered just before anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine administered 1 h before anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: 250 micrograms triazolam orally 1 h before anesthesia (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine administered 3 h before anesthesia
Number of subjects: 40
Study: 2531606

Group type: EXPERIMENTAL
Intervention: Intravenous atropine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium
Number of subjects: 7
Study: 1104900

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard hormonal or other therapies
Number of subjects: 0
Study: 31134822

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU vitamin D3/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 31743954

Group type: EXPERIMENTAL
Intervention: Ideal OC2A and POCA (both within 95% CI of the healthy group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-ideal OC2A and POCA (not within 95% CI of the healthy group)
Number of subjects: 30
Study: 29084247

Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion for 6 hours per day for up to 7 consecutive days
Number of subjects: 100

Group type: COMPARATOR
Intervention: No hemoperfusion (control)
Number of subjects: 100
Study: 25494405

Group type: EXPERIMENTAL
Intervention: A1166C polymorphism in the AT1 gene
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 250
Study: 23406306

Group type: EXPERIMENTAL
Intervention: Nutritional counseling by phone, access to twice‐weekly exercise sessions, information on healthy eating and physical activity provided in pamphlets, evening meetings and an interactive website.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 600
Study: 21726928

Group type: EXPERIMENTAL
Intervention: GnRH agonist (Group AGO)
Number of subjects: 183

Group type: COMPARATOR
Intervention: GnRH antagonist (Group ANTAG)
Number of subjects: 183
Study: 18698212

Group type: EXPERIMENTAL
Intervention: NOS3 rs1800779
Number of subjects: 18436

Group type: EXPERIMENTAL
Intervention: NOS3 rs3918226
Number of subjects: 18436

Group type: EXPERIMENTAL
Intervention: NOS3 rs1799983
Number of subjects: 18436

Group type: EXPERIMENTAL
Intervention: ACE rs1799752
Number of subjects: 18436

Group type: EXPERIMENTAL
Intervention: AGT rs699
Number of subjects: 18436

Group type: EXPERIMENTAL
Intervention: AGTR1 rs5186
Number of subjects: 18436
Study: 16284192

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12851342

Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 (Synvisc)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone sodium phosphate‐betamethasone acetate, Celestone Soluspan)
Number of subjects: 100
Study: 10383511

Group type: EXPERIMENTAL
Intervention: High dose spearmint (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavouring dose spearmint (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8723601

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (2 mg/kg in 15 min followed by 1 mg/kg in 2 h)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 1685992

Group type: EXPERIMENTAL
Intervention: Urapidil (40 mg bolus followed by an infusion of 18 mg.h‐1 for 2 h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Urapidil concentrations
Number of subjects: 6
Study: 6809393

Group type: EXPERIMENTAL
Intervention: Almitrine at a dose of 0.5 mg h‐1 kg‐1 given intravenously over 2 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30259650

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 32
Study: 27662799

Group type: EXPERIMENTAL
Intervention: Randomized long-acting reversible contraception
Number of subjects: 916

Group type: COMPARATOR
Intervention: Randomized short-acting reversible contraception
Number of subjects: 916

Group type: COMPARATOR
Intervention: Preference short-acting reversible contraception
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Method continuers at 12 months (all groups)
Number of subjects: 916
Study: 25778317

Group type: EXPERIMENTAL
Intervention: Conventional fractionated radiotherapy combined with concurrent combination chemotherapy (cisplatin and 5‐fluorouracil)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 200
Study: 24131016

Group type: EXPERIMENTAL
Intervention: Moderate and vigorous physical activity (MVPA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fatigue interference (as an intermediate pathway)
Number of subjects: 240
Study: 22390068

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DN - 114001 (109 cells daily for 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no supplementation after 3 months)
Number of subjects: 0
Study: 19641152

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) with tannic acid
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) alone
Number of subjects: 976

Group type: COMPARATOR
Intervention: No SDF application
Number of subjects: 976
Study: 17692243

Group type: EXPERIMENTAL
Intervention: Threshold device
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Resistive load device
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 15458571

Group type: EXPERIMENTAL
Intervention: Spermicide intervention for contraception for 7 months
Number of subjects: 1514
Study: 11248068

Group type: EXPERIMENTAL
Intervention: Synthetic globo H‐keyhole limpet hemocyanin conjugates plus QS‐21 adjuvant
Number of subjects: 27
Study: 12759987

Group type: EXPERIMENTAL
Intervention: Perineal massage in labour
Number of subjects: 0
Study: 9298561

Group type: EXPERIMENTAL
Intervention: Aerobic workout or aerobic dance
Number of subjects: 63

Group type: COMPARATOR
Intervention: Neutral video watching condition
Number of subjects: 63
Study: 8097925

Group type: EXPERIMENTAL
Intervention: Epanolol (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epanolol (mean 300 mg/day for 10 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epanolol (300 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol (150 mg/day)
Number of subjects: 12
Study: 3520318

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 626

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 626

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (if needed)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Propranolol + Hydrochlorothiazide (if needed)
Number of subjects: 626
Study: 29149756

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Residual anxiety (uncontrollable worry)
Number of subjects: 129
Study: 27422403

Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains (ITCs)
Number of subjects: 605
Study: 25069012

Group type: EXPERIMENTAL
Intervention: Coefficient of Variability (CV)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Number of pumps
Number of subjects: 58
Study: 22475362

Group type: EXPERIMENTAL
Intervention: Bleeding-avoidance strategies (BAS) including direct thrombin inhibitors and vascular closure devices
Number of subjects: 10469

Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors
Number of subjects: 10469

Group type: EXPERIMENTAL
Intervention: Vascular closure devices
Number of subjects: 10469

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 10469

Group type: EXPERIMENTAL
Intervention: Overall risk-adjusted bleeding
Number of subjects: 10469
Study: 19821701

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with an 830-nm diode laser, 40 mW, 1.04 J per point, applied on days 1, 3, 5, and 7 post-surgery
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 28
Study: 18164458

Group type: EXPERIMENTAL
Intervention: Lumbar extensor strengthening exercises
Number of subjects: 0
Study: 15969244

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (CR) 40 mg daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-dose transdermal estradiol (TTSE2) 25 microg every 7 days plus dihydrogesterone 10 mg/day for the last 12 days
Number of subjects: 64
Study: 14686229

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ganciclovir (oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMV immune globulin i.v. and oral acyclovir
Number of subjects: 0
Study: 10570746

Group type: EXPERIMENTAL
Intervention: Goat IgG antiidiotype vaccine SCV 106 (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unspecific goat IgG (controls, n = 21)
Number of subjects: 42
Study: 8966142

Group type: EXPERIMENTAL
Intervention: CT and 1 alpha-OH-D3
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1 alpha-OH-D3 or 1.25(OH)2D3 alone
Number of subjects: 75

Group type: COMPARATOR
Intervention: None of these drugs
Number of subjects: 75
Study: 1679659

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobazam 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lorazepam 1 mg
Number of subjects: 10
Study: 30078034

Group type: EXPERIMENTAL
Intervention: Multicomponent workplace‐delivered intervention
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 231
Study: 26389719

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Training (HIT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 87
Study: 24874991

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 63
Study: 23000709

Group type: EXPERIMENTAL
Intervention: Switched side
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-switched side
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both sides
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mucosal thickness
Number of subjects: 15
Study: 20495473

Group type: EXPERIMENTAL
Intervention: Conditioned placebo dose reduction condition (50% reduced dose/placebo)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Dose reduction only condition (RD)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No reduction condition (full dose)
Number of subjects: 99
Study: 19086953

Group type: EXPERIMENTAL
Intervention: Intensive regimen (80 mg bolus followed by 8 mg/h continuous infusion for 72 h)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard regimen (40 mg bolus daily followed by saline infusion for 72 h)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 474
Study: 16586078

Group type: EXPERIMENTAL
Intervention: FDG whole-body PET scanning
Number of subjects: 33
Study: 14752969

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DBM) putty delivery system
Number of subjects: 10
Study: 11055317

Group type: EXPERIMENTAL
Intervention: Home visitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home visitation combined with early stimulation programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse counselling once a week for 6-8 weeks
Number of subjects: 0
Study: 8922050

Group type: EXPERIMENTAL
Intervention: Ramp protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Incremental protocol
Number of subjects: 20
Study: 1526689

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12267108

Group type: EXPERIMENTAL
Intervention: ML Cu250
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: TCu-220C
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Cu7
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Continuation rates at 24 months: Cu7 (69), TCu-220C (73), ML Cu250 (74).
Number of subjects: 1725
Study: 31396621

Group type: EXPERIMENTAL
Intervention: Intensive interventions (IPC, CM, MM)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Nonintensive interventions (standard IPC, less‐intensive CM and MM)
Number of subjects: 2000
Study: 30412626

Group type: EXPERIMENTAL
Intervention: Active recovery (ACT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Massage (MAS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 46
Study: 27454509

Group type: EXPERIMENTAL
Intervention: Tendon interposition arthroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: K. wire distraction
Number of subjects: 120
Study: 24119718

Group type: EXPERIMENTAL
Intervention: Perioperative alfacalcidol supplementation (group B)
Number of subjects: 219

Group type: COMPARATOR
Intervention: No alfacalcidol supplementation (group A)
Number of subjects: 219
Study: 22336776

Group type: EXPERIMENTAL
Intervention: Nitrate 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrate 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrate 400 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrate 400 mg plus antibacterial toothpaste
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0 mg Nitrate (Control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrate doses (100 mg, 200 mg, 400 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antibacterial toothpaste
Number of subjects: 16
Study: 20129511

Group type: EXPERIMENTAL
Intervention: Amantadine 4 mg/kg/day for 7 days followed by 6 mg/kg/day for 14 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17509511

Group type: EXPERIMENTAL
Intervention: Topical 0.02% mitomycin C (MMC) applied for 15 seconds during PRK
Number of subjects: 15

Group type: COMPARATOR
Intervention: Epi-LASIK (control group)
Number of subjects: 15
Study: 16284692

Group type: EXPERIMENTAL
Intervention: Prophylactic parenteral nutrition (PN)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PN with 0.5 g glutamine/kg as L‐Ala‐L‐Gln
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard PN
Number of subjects: 44

Group type: COMPARATOR
Intervention: PN given ad hoc
Number of subjects: 44
Study: 11907712

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 108
Study: 10542923

Group type: EXPERIMENTAL
Intervention: Anterosuperior quadrant insertion of Shah grommet ventilation tube
Number of subjects: 54

Group type: COMPARATOR
Intervention: Anteroinferior quadrant insertion of Shah grommet ventilation tube
Number of subjects: 54
Study: 7778387

Group type: EXPERIMENTAL
Intervention: Glycine (daily dose 1-2 grams)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 226
Study: 2316281

Group type: EXPERIMENTAL
Intervention: Vaccine with 0.03-3.0 micrograms antigen per dose
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 37045

Group type: EXPERIMENTAL
Intervention: Azatadine maleate 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azatadine maleate 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azatadine maleate 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexchlorpheniramine 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31190327

Group type: EXPERIMENTAL
Intervention: ENR-IV (10 mg/kg, IV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ENR-IM (10 mg/kg, IM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DNX-IV (8 mg/kg, IV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DNX-IM (8 mg/kg, IM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ENR and DNX (IV and IM)
Number of subjects: 24
Study: 28873160

Group type: EXPERIMENTAL
Intervention: Patient-specific reminders group (496 GPs, 10,476 patients)
Number of subjects: 33044

Group type: EXPERIMENTAL
Intervention: Generic reminders group (495 GPs, 10,606 patients)
Number of subjects: 33044

Group type: COMPARATOR
Intervention: Usual care group (455 GPs, 10,147 patients)
Number of subjects: 33044
Study: 26506165

Group type: EXPERIMENTAL
Intervention: Cyclic stimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous stimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 32
Study: 24148291

Group type: EXPERIMENTAL
Intervention: 5% methimazole ointment applied to the skin around the thyroid and an oral placebo
Number of subjects: 144

Group type: COMPARATOR
Intervention: Methimazole tablets and placebo ointment
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 5% methimazole ointment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Methimazole tablets
Number of subjects: 144
Study: 21798557

Group type: EXPERIMENTAL
Intervention: 7.5 mg of 1‐month depot leuprolide acetate (DL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 11.25 mg of 3‐month depot leuprolide acetate (DL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 22.5 mg of 3‐month depot leuprolide acetate (DL)
Number of subjects: 54
Study: 19689546

Group type: EXPERIMENTAL
Intervention: Comfort O2 (ONSI‐56) lenses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Boston XO lenses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable (no specific control group mentioned)
Number of subjects: 30
Study: 16867922

Group type: EXPERIMENTAL
Intervention: Major depressive disorder with concurrent substance use disorder (SUD)
Number of subjects: 2541

Group type: COMPARATOR
Intervention: Major depressive disorder without concurrent substance use disorder (SUD)
Number of subjects: 2541
Study: 12552189

Group type: EXPERIMENTAL
Intervention: propofol-fentanyl
Number of subjects: 117

Group type: COMPARATOR
Intervention: isoflurane-fentanyl
Number of subjects: 117
Study: 10506597

Group type: EXPERIMENTAL
Intervention: Sequential therapy with doxorubicin 75 mg/m(2) every 2 weeks for three cycles followed by docetaxel 100 mg/m(2) every 2 weeks for three cycles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination therapy with doxorubicin 56 mg/m(2) plus docetaxel 75 mg/m(2) every 3 weeks for four cycles
Number of subjects: 40
Study: 8891961

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (COTEE)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fick method (COFICK)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thermodilution (COTD)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Delta COTEE
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Delta COFICK
Number of subjects: 13
Study: 1671951

Group type: EXPERIMENTAL
Intervention: Paracetamol liquid 10-15 mg/kg every 4 hours as needed for fever
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 225
Study: 6383513

Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30297537

Group type: EXPERIMENTAL
Intervention: Hemorrhagic infarction type 2
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Parenchymal hematoma type 2
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Hemorrhagic infarction type 1
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Parenchymal hematoma type 1
Number of subjects: 478
Study: 28985094

Group type: EXPERIMENTAL
Intervention: Nonoperative management for first-time dislocation without osteochondral fragment or loose body
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for first-time dislocation with operative osteochondral fracture requiring excision or repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent instability, favoring medial reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bony procedures to correct underlying bony deformities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral release for patellar instability
Number of subjects: 0
Study: 26965534

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 24220913

Group type: EXPERIMENTAL
Intervention: CRP concentrations ≥ 10.0 mg/L
Number of subjects: 2919